Literature DB >> 17912949

Ex vivo expansion and transplantation of hematopoietic stem/progenitor cells supported by mesenchymal stem cells from human umbilical cord blood.

Guo-Ping Huang1, Zhi-Jun Pan, Bing-Bing Jia, Qiang Zheng, Chun-Gang Xie, Jiang-Hong Gu, Ian K McNiece, Jin-Fu Wang.   

Abstract

Human mesenchymal stem cells (MSCs) are multipotential and are detected in bone marrow (BM), adipose tissue, placenta, and umbilical cord blood (UCB). In this study, we examined the ability of UCB-derived MSCs (UCB-MSCs) to support ex vivo expansion of hematopoietic stem/progenitor cells (HSPCs) from UCB and the engraftment of expanded HSPCs in NOD/SCID mice. The result showed that UCB-MSCs supported the proliferation and differentiation of CD34+ cells in vitro. The number of expanded total nucleated cells (TNCs) in MSC-based culture was twofold higher than cultures without MSC (control cultures). UCB-MSCs increased the expansion capabilities of CD34+ cells, long-term culture-initiating cells (LTC-ICs), granulocyte-macrophage colony-forming cells (GM-CFCs), and high proliferative potential colony-forming cells (HPP-CFCs) compared to control cultures. The expanded HSPCs were transplanted into lethally irradiated NOD/SCID mice to assess the effects of expanded cells on hematopoietic recovery. The number of white blood cells (WBCs) in the peripheral blood of mice transplanted with expanded cells from both the MSC-based and control cultures returned to pretreatment levels at day 25 posttransplant and then decreased. The WBC levels returned to pretreatment levels again at days 45-55 posttransplant. The level of human CD45+ cell engraftment in primary recipients transplanted with expanded cells from the MSC-based cultures was significantly higher than recipients transplanted with cells from the control cultures. Serial transplantation demonstrated that the expanded cells could establish long-term engraftment of hematopoietic cells. UCB-MSCs similar to those derived from adult bone marrow may provide novel targets for cellular and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912949     DOI: 10.3727/000000007783465073

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  19 in total

1.  Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth.

Authors:  Xu Cui; Michael Chopp; Amjad Shehadah; Alex Zacharek; Nicole Kuzmin-Nichols; Cyndy Davis Sanberg; Junhao Dai; Chunling Zhang; Yuji Ueno; Cynthia Roberts; Jieli Chen
Journal:  Cell Transplant       Date:  2012-03-08       Impact factor: 4.064

2.  Mesenchymal stem cells secreting angiopoietin-like-5 support efficient expansion of human hematopoietic stem cells without compromising their repopulating potential.

Authors:  Maroun Khoury; Adam Drake; Qingfeng Chen; Di Dong; Ilya Leskov; Maria F Fragoso; Yan Li; Bettina P Iliopoulou; William Hwang; Harvey F Lodish; Jianzhu Chen
Journal:  Stem Cells Dev       Date:  2011-01-31       Impact factor: 3.272

Review 3.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

Review 4.  Communications between bone cells and hematopoietic stem cells.

Authors:  R L Porter; L M Calvi
Journal:  Arch Biochem Biophys       Date:  2008-04-07       Impact factor: 4.013

Review 5.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

6.  Preclinical transplantation and safety of HS/PCs expanded from human umbilical cord blood.

Authors:  Chun-Juan Guo; Ying Gao; Di Hou; Dong-Yan Shi; Xiang-Min Tong; Dan Shen; Yong-Mei Xi; Jin-Fu Wang
Journal:  World J Stem Cells       Date:  2011-05-26       Impact factor: 5.326

7.  Combination stem cell therapy for heart failure.

Authors:  Thomas E Ichim; Fabio Solano; Fabian Lara; Jorge Paz Rodriguez; Octav Cristea; Boris Minev; Famela Ramos; Erik J Woods; Michael P Murphy; Doru T Alexandrescu; Amit N Patel; Neil H Riordan
Journal:  Int Arch Med       Date:  2010-04-14

8.  Perivascular support of human hematopoietic stem/progenitor cells.

Authors:  Mirko Corselli; Chee Jia Chin; Chintan Parekh; Arineh Sahaghian; Wenyuan Wang; Shundi Ge; Denis Evseenko; Xiaoyan Wang; Elisa Montelatici; Lorenza Lazzari; Gay M Crooks; Bruno Péault
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

9.  Human CD34(lo)CD133(lo) fetal liver cells support the expansion of human CD34(hi)CD133(hi) hematopoietic stem cells.

Authors:  Kylie Su Mei Yong; Choong Tat Keng; Shu Qi Tan; Eva Loh; Kenneth Te Chang; Thiam Chye Tan; Wanjin Hong; Qingfeng Chen
Journal:  Cell Mol Immunol       Date:  2015-05-25       Impact factor: 11.530

10.  Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages.

Authors:  Alexandra Briquet; Sophie Dubois; Sandrine Bekaert; Marie Dolhet; Yves Beguin; André Gothot
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.